Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...

Johns Hopkins University School of Medicine researchers have discovered a dual regulatory mechanism safeguarding ...

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

MIT researchers discovered a way to treat Fragile X syndrome by targeting NMDA receptors, restoring synaptic balance and reducing seizures in mice. Augmenting GluN2B receptor signaling corrected ...

A photothermal, nanoparticle-based deep brain stimulation system restored motor skills in mice with Parkinson’s-like disease ...

在慢性疼痛过程中脊髓背角区（SDH）的星形胶质细胞增生比神经损伤后的小胶质细胞增生更明显。为探究SDH区星形胶质细胞Gpr37l1是否参与疼痛，研究人员首先通过单细胞测序发现Gpr37l1富集表达SDH区星形胶质细胞，免疫荧光实验证实Gpr37l1可 ...

New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

Ketamine has received a Hollywood makeover. It used to be known as a rave drug (street name special K) and cat anesthetic.

The discovery opens up opportunities to study the therapeutic properties of ibogaine and related compounds. Ibogaine, a ...

Nerve cells called pro-opiomelanocortin (POMC) neurons were found to be responsible for post-feeding sugar consumption.

Ibogaine—a psychoactive plant derivative—has attracted attention for its anti-addictive and anti-depressant properties. But ibogaine is a finite resource, extracted from plants native to Africa like ...